8th May 2006 07:02
Skyepharma PLC08 May 2006 For Immediate Release 8 May, 2006 SkyePharma PLC SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM) LONDON, ENGLAND, 8 May, 2006 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) and KosPharmaceuticals, Inc. (Nasdaq: KOSP, "Kos") will host a joint teleconferencelater today to discuss the US development and marketing agreement for Flutiform(TM) announced this morning. SkyePharma's Chief Executive, Frank Condella, and Adrian Adams, President and Chief Executive of Kos, will present further information on the collaboration including information on each company'scapabilities in the field of inhalation therapies. The conference call will be at 1330 BST / 0830 EDT today. The conference callwill be available live via the Internet by accessing the website of eithercompany at www.kospharm.com or www.skyepharma.com where the presentation slideswill also be available. Please go to the respective website at least fifteenminutes prior to the call to register, download and install any necessary audiosoftware. Those who cannot access the webcast can participate by telephone bycalling +1-913-312-1295, confirmation code 6963745. A replay will also beavailable on both websites or by calling +1-719-457-0820 and enteringconfirmation code 6963745 from 1130 EDT today until 2359 EDT on Friday, May 12,2006. For further information please contact: SkyePharma PLC +44 207 491 1777Frank Condella, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court / Rebecca Skye Dietrich Notes for editors About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now twelve approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L